{"id":"W4381943622","doi":"10.1038/s41591-023-02427-z","title":"The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":101,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Esperion Therapeutics; Allergan; HLS Therapeutics; Idorsia Pharmaceuticals; Moderna; MyoKardia; Novo Nordisk; Medicines Company; St. Jude Medical; Regeneron Pharmaceuticals; Eli Lilly and Company; AstraZeneca; CSL Behring; Sanofi; Amgen; Pfizer; Ironwood Pharmaceuticals, Incorporated; 89bio; Amarin Corporation; Boston Scientific Corporation","keywords":"Placebo; Medicine; Internal medicine; Hypertriglyceridemia; Gastroenterology; Clinical endpoint; Adverse effect; Confidence interval; Randomized controlled trial; Cholesterol; Triglyceride; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002432861,0.0001935737,0.0004596751,0.0001701906,0.0001101425,0.00001467514,0.0003751852,0.0005001447,0.00006776723],"category_scores_gemma":[0.006595748,0.0001080158,0.0001327042,0.0006824649,0.0003690369,0.000003319076,0.0001392925,0.0008936514,0.00002790506],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002843829,"about_ca_system_score_gemma":0.0001408023,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003581468,"about_ca_topic_score_gemma":0.00008390745,"domain_scores_codex":[0.997856,0.0004443077,0.0004008305,0.0003829812,0.0004590271,0.0004568408],"domain_scores_gemma":[0.9985952,0.0006595891,0.00008288979,0.0004471789,0.00009881497,0.0001162887],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6738232,0.00008274228,0.0001637451,0.00003598054,0.0001334951,0.0001180929,0.0001195186,0.000009062956,0.2462149,0.0003019341,0.07139407,0.007603218],"study_design_scores_gemma":[0.8980004,0.001074493,0.0003464059,0.0000658375,0.00003391398,0.00003652576,0.0001310055,0.0002855974,0.01540889,0.0004562323,0.08395235,0.0002083607],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9848565,0.003702659,0.00002421074,0.007479651,0.0007622777,0.00125118,0.000017213,0.00003640221,0.001869887],"genre_scores_gemma":[0.9939749,0.0009945012,0.0000225779,0.0004360069,0.001238629,0.0001337019,0.0002285825,0.00002953175,0.002941576],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.230806,"threshold_uncertainty_score":0.7896203,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01399942668264709,"score_gpt":0.3551137585604487,"score_spread":0.3411143318778016,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}